NCIt definition : An orally bioavailable benzimidazole targeting the platelet-derived growth factor
receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3),
with potential antineoplastic activity. Upon oral administration, crenolanib binds
to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result
in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results
in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3
overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are
upregulated or mutated in many tumor cell types.;
UNII : LQF7I567TQ;
InChIKey : DYNHJHQFHQTFTP-UHFFFAOYSA-N;
CAS number : 670220-88-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 670220-88-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;